Catalyst Pharmaceuticals, Inc. (CPRX)
USD 23.18
(-3.86%)
USD 23.18
(-3.86%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 471.9 Million USD | 25.63% |
| 2022 | 375.63 Million USD | 57.97% |
| 2021 | 237.78 Million USD | 23.62% |
| 2020 | 192.35 Million USD | 71.17% |
| 2019 | 112.37 Million USD | 85.9% |
| 2018 | 60.44 Million USD | -29.21% |
| 2017 | 85.38 Million USD | 104.73% |
| 2016 | 41.7 Million USD | -30.61% |
| 2015 | 60.1 Million USD | 36.88% |
| 2014 | 43.9 Million USD | 73.07% |
| 2013 | 25.36 Million USD | 51.11% |
| 2012 | 16.78 Million USD | 168.66% |
| 2011 | 6.24 Million USD | 7.16% |
| 2010 | 5.83 Million USD | -26.8% |
| 2009 | 7.96 Million USD | -33.8% |
| 2008 | 12.03 Million USD | -27.86% |
| 2007 | 16.67 Million USD | -19.11% |
| 2006 | 20.61 Million USD | 2511.88% |
| 2005 | 789.45 Thousand USD | 325.86% |
| 2004 | 185.37 Thousand USD | 0.0% |
| 2002 | 111.58 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 706.36 Million USD | 9.23% |
| 2024 Q1 | 646.67 Million USD | 37.03% |
| 2023 Q2 | 443.89 Million USD | 9.0% |
| 2023 FY | 471.9 Million USD | 25.63% |
| 2023 Q1 | 407.22 Million USD | 8.41% |
| 2023 Q4 | 471.9 Million USD | 14.2% |
| 2023 Q3 | 413.21 Million USD | -6.91% |
| 2022 Q1 | 246.97 Million USD | 3.86% |
| 2022 FY | 375.63 Million USD | 57.97% |
| 2022 Q2 | 267.3 Million USD | 8.23% |
| 2022 Q3 | 333.11 Million USD | 24.62% |
| 2022 Q4 | 375.63 Million USD | 12.76% |
| 2021 Q2 | 209.13 Million USD | 6.04% |
| 2021 Q1 | 197.21 Million USD | 2.53% |
| 2021 FY | 237.78 Million USD | 23.62% |
| 2021 Q3 | 223.24 Million USD | 6.75% |
| 2021 Q4 | 237.78 Million USD | 6.51% |
| 2020 Q2 | 131.41 Million USD | 11.48% |
| 2020 FY | 192.35 Million USD | 71.17% |
| 2020 Q4 | 192.35 Million USD | 10.0% |
| 2020 Q3 | 174.85 Million USD | 33.06% |
| 2020 Q1 | 117.87 Million USD | 4.9% |
| 2019 Q1 | 61.07 Million USD | 1.04% |
| 2019 Q2 | 78.23 Million USD | 28.09% |
| 2019 Q3 | 96.69 Million USD | 23.59% |
| 2019 FY | 112.37 Million USD | 85.9% |
| 2019 Q4 | 112.37 Million USD | 16.22% |
| 2018 Q1 | 79.12 Million USD | -7.33% |
| 2018 FY | 60.44 Million USD | -29.21% |
| 2018 Q4 | 60.44 Million USD | -10.72% |
| 2018 Q3 | 67.7 Million USD | -8.85% |
| 2018 Q2 | 74.28 Million USD | -6.12% |
| 2017 Q1 | 37.69 Million USD | -9.61% |
| 2017 FY | 85.38 Million USD | 104.73% |
| 2017 Q4 | 85.38 Million USD | 146.56% |
| 2017 Q3 | 34.63 Million USD | -3.75% |
| 2017 Q2 | 35.98 Million USD | -4.55% |
| 2016 Q1 | 53.66 Million USD | -10.71% |
| 2016 Q2 | 48.94 Million USD | -8.8% |
| 2016 Q4 | 41.7 Million USD | -7.96% |
| 2016 Q3 | 45.31 Million USD | -7.41% |
| 2016 FY | 41.7 Million USD | -30.61% |
| 2015 Q1 | 76.04 Million USD | 73.2% |
| 2015 Q2 | 68.33 Million USD | -10.14% |
| 2015 Q4 | 60.1 Million USD | -6.91% |
| 2015 FY | 60.1 Million USD | 36.88% |
| 2015 Q3 | 64.56 Million USD | -5.52% |
| 2014 Q4 | 43.9 Million USD | -4.22% |
| 2014 FY | 43.9 Million USD | 73.07% |
| 2014 Q3 | 45.84 Million USD | -0.18% |
| 2014 Q2 | 45.92 Million USD | 106.61% |
| 2014 Q1 | 22.22 Million USD | -12.38% |
| 2013 Q4 | 25.36 Million USD | -11.59% |
| 2013 FY | 25.36 Million USD | 51.11% |
| 2013 Q3 | 28.69 Million USD | 128.73% |
| 2013 Q2 | 12.54 Million USD | -13.29% |
| 2013 Q1 | 14.46 Million USD | -13.83% |
| 2012 FY | 16.78 Million USD | 168.66% |
| 2012 Q4 | 16.78 Million USD | 38.69% |
| 2012 Q3 | 12.1 Million USD | 57.13% |
| 2012 Q1 | 4.98 Million USD | -20.17% |
| 2012 Q2 | 7.7 Million USD | 54.43% |
| 2011 Q2 | 5.61 Million USD | -21.6% |
| 2011 Q3 | 4.29 Million USD | -23.39% |
| 2011 FY | 6.24 Million USD | 7.16% |
| 2011 Q1 | 7.15 Million USD | 22.71% |
| 2011 Q4 | 6.24 Million USD | 45.41% |
| 2010 FY | 5.83 Million USD | -26.8% |
| 2010 Q3 | 6.41 Million USD | 8.53% |
| 2010 Q1 | 7.03 Million USD | -11.67% |
| 2010 Q2 | 5.91 Million USD | -16.0% |
| 2010 Q4 | 5.83 Million USD | -9.1% |
| 2009 Q2 | 6.48 Million USD | -29.91% |
| 2009 Q3 | 5.07 Million USD | -21.65% |
| 2009 Q4 | 7.96 Million USD | 56.88% |
| 2009 FY | 7.96 Million USD | -33.8% |
| 2009 Q1 | 9.24 Million USD | -23.15% |
| 2008 Q2 | 13.53 Million USD | -12.62% |
| 2008 Q1 | 15.48 Million USD | -7.14% |
| 2008 Q4 | 12.03 Million USD | -21.6% |
| 2008 Q3 | 15.34 Million USD | 13.4% |
| 2008 FY | 12.03 Million USD | -27.86% |
| 2007 FY | 16.67 Million USD | -19.11% |
| 2007 Q1 | 19.37 Million USD | -6.02% |
| 2007 Q2 | 18.24 Million USD | -5.84% |
| 2007 Q3 | 17.59 Million USD | -3.58% |
| 2007 Q4 | 16.67 Million USD | -5.19% |
| 2006 Q2 | 365.11 Thousand USD | 0.0% |
| 2006 Q4 | 20.61 Million USD | 487.11% |
| 2006 Q3 | 3.51 Million USD | 861.9% |
| 2006 FY | 20.61 Million USD | 2511.88% |
| 2005 Q4 | 789.45 Thousand USD | 0.0% |
| 2005 FY | 789.45 Thousand USD | 325.86% |
| 2004 Q4 | 185.37 Thousand USD | 0.0% |
| 2004 FY | 185.37 Thousand USD | 0.0% |
| 2002 FY | 111.58 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 68.288% |
| Alkermes plc | 2.13 Billion USD | 77.909% |
| Agenus Inc. | 313.91 Million USD | -50.331% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 87.678% |
| Aptorum Group Limited | 20.64 Million USD | -2186.361% |
| Ardelyx, Inc. | 297.57 Million USD | -58.582% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 38.357% |
| Bicycle Therapeutics plc | 595.34 Million USD | 20.734% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -540.291% |
| ChromaDex Corporation | 54.96 Million USD | -758.575% |
| Chimerix, Inc. | 212.77 Million USD | -121.788% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1569.144% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -7.016% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 78.834% |
| Precision BioSciences, Inc. | 159.78 Million USD | -195.346% |
| Dyadic International, Inc. | 8.21 Million USD | -5641.495% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1386.79% |
| Fortress Biotech, Inc. | 167.52 Million USD | -181.692% |
| Lantern Pharma Inc. | 43.64 Million USD | -981.175% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -192.498% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -3153.04% |
| Incyte Corporation | 6.78 Billion USD | 93.042% |
| IO Biotech, Inc. | 150.71 Million USD | -213.106% |
| Jaguar Health, Inc. | 50.76 Million USD | -829.628% |
| Novavax, Inc. | 1.85 Billion USD | 74.565% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -24.053% |
| Opthea Limited | 188.79 Million USD | -149.962% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 43.353% |
| ContextLogic Inc. | 423 Million USD | -11.562% |
| MiMedx Group, Inc. | 239.04 Million USD | -97.412% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -171.639% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -9028.323% |
| NextCure, Inc. | 129.41 Million USD | -264.638% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -774.744% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1184.835% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1360.967% |
| Vaxcyte, Inc. | 1.4 Billion USD | 66.482% |
| PDS Biotechnology Corporation | 59.39 Million USD | -694.589% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 26.327% |
| Pharming Group N.V. | 462.85 Million USD | -1.956% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1120.028% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 24.922% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2393.739% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2393.739% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -185.451% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -942.036% |
| Acelyrin, Inc. | 742.69 Million USD | 36.46% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -7064.736% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -7270.092% |
| Summit Therapeutics Inc. | 202.94 Million USD | -132.525% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -534.505% |
| Senti Biosciences, Inc. | 119.48 Million USD | -294.954% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -106.667% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -180.606% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -5611.086% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -9785.42% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -0.579% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -281.638% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -71.634% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 0.197% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -4570.035% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -119.997% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -41582.043% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -14.031% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2268.398% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -27.534% |
| MEI Pharma, Inc. | 41.37 Million USD | -1040.561% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1356.233% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -38.471% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -302.565% |
| Fortress Biotech, Inc. | 167.52 Million USD | -181.692% |
| Precigen, Inc. | 151.04 Million USD | -212.432% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1287.227% |
| AlloVir, Inc. | 190.79 Million USD | -147.336% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -25.357% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 6.778% |
| ImmuCell Corporation | 43.8 Million USD | -977.214% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 27.322% |
| Onconetix, Inc. | 88.82 Million USD | -431.298% |
| PureTech Health plc | 693.97 Million USD | 31.999% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -383.091% |
| Elevation Oncology, Inc. | 89.09 Million USD | -429.691% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -7508.949% |
| Seer, Inc. | 436.26 Million USD | -8.169% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -478.339% |
| Innoviva, Inc. | 1.24 Billion USD | 62.05% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -256.363% |
| ESSA Pharma Inc. | 149.12 Million USD | -216.457% |
| GlycoMimetics, Inc. | 45.31 Million USD | -941.359% |
| GT Biopharma, Inc. | 14.1 Million USD | -3244.723% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -53.27% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -95.243% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -830.838% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -395.638% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -74617.537% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 16.674% |
| Aptose Biosciences Inc. | 12.92 Million USD | -3551.812% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -2033.947% |
| Soligenix, Inc. | 9.79 Million USD | -4716.692% |
| Century Therapeutics, Inc. | 360.69 Million USD | -30.834% |
| Kura Oncology, Inc. | 448.93 Million USD | -5.117% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -73.4% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2628.575% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -325.481% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -130.029% |
| Autolus Therapeutics plc | 375.38 Million USD | -25.714% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -87.536% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -32.863% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -860.488% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 28.622% |
| GRI Bio, Inc. | 2.95 Million USD | -15864.378% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -4349.759% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -176.754% |
| IGM Biosciences, Inc. | 423.41 Million USD | -11.454% |
| INmune Bio, Inc. | 57 Million USD | -727.892% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -112.087% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -462.187% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1706.906% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -6755.93% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -527.319% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -220.463% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -185.133% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 25.047% |
| Verastem, Inc. | 149.71 Million USD | -215.197% |
| Abeona Therapeutics Inc. | 64 Million USD | -637.332% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 7.858% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -205.526% |
| Histogen Inc. | 19.07 Million USD | -2374.215% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1983.459% |
| Surrozen, Inc. | 46.08 Million USD | -924.104% |
| Organovo Holdings, Inc. | 6.34 Million USD | -7332.777% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10852.625% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -227.652% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3898.534% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -526.969% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -5439.302% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -30.013% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2508.028% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -9.899% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3641.813% |
| Apollomics, Inc. | 55.38 Million USD | -752.018% |
| Amarin Corporation plc | 831.68 Million USD | 43.259% |
| Mesoblast Limited | 669.15 Million USD | 29.477% |
| Turnstone Biologics Corp. | 112.81 Million USD | -318.302% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 18.037% |
| Synaptogenix, Inc. | 31.11 Million USD | -1416.719% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3773.17% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 13.895% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7936.206% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -6324.735% |
| Exelixis, Inc. | 2.94 Billion USD | 83.962% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1956.867% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -29.453% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 40.169% |
| NLS Pharmaceutics AG | 1.84 Million USD | -25454.886% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -5814.634% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -3111.344% |
| Gritstone bio, Inc. | 177.76 Million USD | -165.461% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -394.765% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2541.921% |
| Avid Bioservices, Inc. | 336.55 Million USD | -40.216% |
| Insmed Incorporated | 1.32 Billion USD | 64.514% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -4801.227% |
| MediWound Ltd. | 66.45 Million USD | -610.072% |
| OmniAb, Inc. | 401.98 Million USD | -17.394% |
| Alector, Inc. | 621.82 Million USD | 24.11% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -31.597% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -8674.768% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -732.405% |
| Zai Lab Limited | 1.03 Billion USD | 54.462% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 1.368% |
| Aura Biosciences, Inc. | 255.07 Million USD | -85.007% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 37.081% |
| Immunic, Inc. | 54.29 Million USD | -769.09% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -77.259% |
| Veracyte, Inc. | 1.13 Billion USD | 58.525% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3891.506% |
| FibroGen, Inc. | 423.52 Million USD | -11.423% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13333.163% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -9862.98% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -8591.572% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 95.858% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -5259.534% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 8.802% |
| TG Therapeutics, Inc. | 329.58 Million USD | -43.181% |
| Galecto, Inc. | 38.22 Million USD | -1134.486% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1545.651% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 89.169% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -100.467% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1799.634% |
| XBiotech Inc. | 227.24 Million USD | -107.666% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -394.765% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -230.931% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -65.051% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -269.055% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -23.536% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 68.35% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -29.346% |
| Vaxxinity, Inc. | 44.35 Million USD | -963.98% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 8.715% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2435.862% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -54.698% |
| NexImmune, Inc. | 8.59 Million USD | -5391.154% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -4304.094% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2655.277% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.573% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -2030.397% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -120203.111% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -172.261% |
| Ainos, Inc. | 31.84 Million USD | -1382.036% |
| Pluri Inc. | 39.52 Million USD | -1093.885% |
| Prothena Corporation plc | 696.38 Million USD | 32.234% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -66.978% |
| Celularity Inc. | 143.88 Million USD | -227.966% |
| Rallybio Corporation | 115.62 Million USD | -308.153% |
| Cue Biopharma, Inc. | 61.53 Million USD | -666.954% |
| MeiraGTx Holdings plc | 458.16 Million USD | -2.999% |
| Omeros Corporation | 378.26 Million USD | -24.754% |
| Humacyte, Inc. | 128.22 Million USD | -268.036% |
| Immunocore Holdings plc | 597 Million USD | 20.954% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1409.668% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -588.614% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 55.024% |
| CalciMedica, Inc. | 12.18 Million USD | -3772.852% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -86.047% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -176.118% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -51.722% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 16.521% |
| Pulmatrix, Inc. | 33.95 Million USD | -1289.678% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1638.403% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -235.023% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 63.727% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -262.478% |
| Cytokinetics, Incorporated | 824.31 Million USD | 42.752% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2134.091% |
| Nutriband Inc. | 7.51 Million USD | -6177.735% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -497.699% |
| Vor Biopharma Inc. | 209.82 Million USD | -124.902% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 93.466% |
| Evogene Ltd. | 51.1 Million USD | -823.479% |
| ProKidney Corp. | 420.55 Million USD | -12.211% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -760.626% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4856.862% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 13.63% |
| CorMedix Inc. | 82.05 Million USD | -475.076% |
| BioLineRx Ltd. | 63.92 Million USD | -638.22% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -17.224% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1573.429% |
| Atai Life Sciences N.V. | 293.47 Million USD | -60.798% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -189.284% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -270.361% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 16.035% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -387.916% |
| MediciNova, Inc. | 66.26 Million USD | -612.098% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -436.575% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10475.267% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4983.441% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 19.776% |
| Biomea Fusion, Inc. | 199.92 Million USD | -136.04% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 75.204% |
| Mereo BioPharma Group plc | 66.49 Million USD | -609.645% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 2.719% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 23.002% |
| Absci Corporation | 234.48 Million USD | -101.257% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6351.224% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -38.841% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -185.862% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 10.339% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -69.938% |
| Allakos Inc. | 243.61 Million USD | -93.714% |
| Imunon, Inc. | 21.91 Million USD | -2053.05% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -83.127% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 24.072% |
| BioAtla, Inc. | 119.65 Million USD | -294.38% |
| NLS Pharmaceutics AG | 1.84 Million USD | -25454.886% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -14555.497% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 26.59% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -391.903% |
| XOMA Corporation | 234.3 Million USD | -101.411% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -113.306% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -274.994% |
| aTyr Pharma, Inc. | 122.06 Million USD | -286.597% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -206.626% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 18.675% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 3.776% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -327.185% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -3013.344% |
| Akari Therapeutics, Plc | 4.35 Million USD | -10735.982% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2669.841% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 72.774% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -15201.853% |
| UroGen Pharma Ltd. | 178.31 Million USD | -164.654% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -0.249% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -84818.888% |
| Orgenesis Inc. | 14.55 Million USD | -3142.901% |
| Entera Bio Ltd. | 11.76 Million USD | -3911.109% |
| GH Research PLC | 226.3 Million USD | -108.532% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -762.813% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -339.245% |
| Xencor, Inc. | 952.69 Million USD | 50.466% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -5962.704% |
| Replimune Group, Inc. | 487.72 Million USD | 3.243% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -5746.881% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 27.224% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -15201.853% |
| Portage Biotech Inc. | 7.77 Million USD | -5966.422% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10475.267% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -70.397% |
| OncoCyte Corporation | 74.89 Million USD | -530.117% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -23109.515% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -8055.108% |
| Purple Biotech Ltd. | 44.3 Million USD | -965.205% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1282.837% |
| scPharmaceuticals Inc. | 94.47 Million USD | -399.483% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2515.174% |
| HilleVax, Inc. | 344.43 Million USD | -37.009% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -14758.533% |
| Tharimmune, Inc. | 10.94 Million USD | -4211.073% |
| Genprex, Inc. | 10.67 Million USD | -4322.501% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 4.895% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -390.283% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -19352.061% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -11229.101% |
| OKYO Pharma Limited | 1.54 Million USD | -30518.181% |
| Savara Inc. | 177.56 Million USD | -165.767% |
| Curis, Inc. | 77.28 Million USD | -510.63% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2117.377% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -637.945% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -5736.099% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2336.152% |
| BeiGene, Ltd. | 5.8 Billion USD | 91.871% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3777.944% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 77.405% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -31.836% |
| Erasca, Inc. | 395.29 Million USD | -19.38% |
| bluebird bio, Inc. | 619.16 Million USD | 23.783% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10815.261% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 93.102% |
| DBV Technologies S.A. | 182.98 Million USD | -157.892% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10815.261% |
| Moderna, Inc. | 18.42 Billion USD | 97.439% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2490.476% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -3973.08% |
| Molecular Templates, Inc. | 35.38 Million USD | -1233.711% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -241.306% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 40.183% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -55.358% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -353.992% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -1.349% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -50.559% |
| MacroGenics, Inc. | 306.82 Million USD | -53.806% |
| RenovoRx, Inc. | 1.46 Million USD | -32090.109% |
| Adicet Bio, Inc. | 207.29 Million USD | -127.65% |
| Prime Medicine, Inc. | 193.85 Million USD | -143.438% |
| Aditxt, Inc. | 44.57 Million USD | -958.602% |
| Adagene Inc. | 115.72 Million USD | -307.77% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10494.678% |
| Quantum-Si incorporated | 298.25 Million USD | -58.225% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 68.274% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -6021.41% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -34.339% |
| SciSparc Ltd. | 11.18 Million USD | -4120.238% |
| Vericel Corporation | 353.65 Million USD | -33.436% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3764.097% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -729.353% |
| Generation Bio Co. | 374.75 Million USD | -25.923% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -85.304% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -197.607% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -38.241% |
| Invivyd, Inc. | 229.18 Million USD | -105.91% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 44.086% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3777.848% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -158.735% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2210.551% |
| 2seventy bio, Inc. | 565.42 Million USD | 16.54% |
| ADMA Biologics, Inc. | 329.18 Million USD | -43.357% |
| Clene Inc. | 52.34 Million USD | -801.601% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -703.46% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -263.302% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4983.441% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 27.81% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -355.46% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -261.931% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -383.749% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -564.686% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -94.558% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 75.924% |
| Evaxion Biotech A/S | 12.88 Million USD | -3561.424% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -87.22% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 37.304% |
| Trevena, Inc. | 40.6 Million USD | -1062.189% |
| Surrozen, Inc. | 46.08 Million USD | -924.104% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -108.941% |
| Cingulate Inc. | 3.49 Million USD | -13416.129% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2737.856% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -618.385% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3938.7% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -75.746% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 36.991% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -274.851% |
| Clearmind Medicine Inc. | 4.32 Million USD | -10812.686% |
| Kronos Bio, Inc. | 213.27 Million USD | -121.263% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -195.341% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5412.539% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -28.065% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2129.164% |
| ImmunityBio, Inc. | 504.45 Million USD | 6.452% |
| Korro Bio, Inc. | 221.66 Million USD | -112.894% |
| Kineta, Inc. | 10.28 Million USD | -4490.089% |
| BioVie Inc. | 25.2 Million USD | -1772.027% |
| Codexis, Inc. | 136.56 Million USD | -245.565% |
| Celularity Inc. | 143.88 Million USD | -227.966% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 25.725% |
| Celcuity Inc. | 191.21 Million USD | -146.788% |
| Virax Biolabs Group Limited | 5.48 Million USD | -8505.209% |
| Cibus, Inc. | 544.41 Million USD | 13.318% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -274.845% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2197.055% |
| IN8bio, Inc. | 33.7 Million USD | -1299.944% |
| Kodiak Sciences Inc. | 479.37 Million USD | 1.557% |
| Annexon, Inc. | 297.67 Million USD | -58.531% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -172.763% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -243.282% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2147.925% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 84.218% |
| Eyenovia, Inc. | 28.77 Million USD | -1539.74% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -104.707% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6432.489% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -674.558% |
| Arcellx, Inc. | 825.13 Million USD | 42.808% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -478.055% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -2.084% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1434.657% |
| Moolec Science SA | 24.05 Million USD | -1862.086% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -52.167% |
| Geron Corporation | 394.07 Million USD | -19.75% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -363.973% |
| Royalty Pharma plc | 16.38 Billion USD | 97.119% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 20.684% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -6646.526% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3823.627% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -108.753% |
| Humacyte, Inc. | 128.22 Million USD | -268.036% |
| Structure Therapeutics Inc. | 482.01 Million USD | 2.097% |
| 89bio, Inc. | 596.26 Million USD | 20.857% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -87.152% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -25408.486% |
| Genelux Corporation | 27.89 Million USD | -1591.847% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -427.842% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -105.688% |
| Notable Labs, Ltd. | 19.54 Million USD | -2314.958% |
| Liquidia Corporation | 120.43 Million USD | -291.848% |
| Mustang Bio, Inc. | 17.74 Million USD | -2559.83% |
| Immunovant, Inc. | 666.71 Million USD | 29.219% |
| Quantum-Si incorporated | 298.25 Million USD | -58.225% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -226.803% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -771.32% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -168.822% |
| Acasti Pharma Inc. | 73.3 Million USD | -543.802% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -10266.386% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1706.906% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 51.087% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -8992.764% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1971.494% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -814.495% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -161.168% |
| PepGen Inc. | 143.05 Million USD | -229.885% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1134.809% |
| United Therapeutics Corporation | 7.16 Billion USD | 93.416% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2359.771% |
| Solid Biosciences Inc. | 164.93 Million USD | -186.11% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7936.206% |
| Immuneering Corporation | 102.58 Million USD | -360.018% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10852.625% |
| Silo Pharma, Inc. | 7.74 Million USD | -5992.156% |
| Belite Bio, Inc | 94.64 Million USD | -398.623% |
| XOMA Corporation | 234.3 Million USD | -101.411% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -102.372% |
| Bionomics Limited | 27.64 Million USD | -1606.772% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -17.564% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -339.441% |
| uniQure N.V. | 831.68 Million USD | 43.259% |
| Cassava Sciences, Inc. | 151.66 Million USD | -211.155% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10494.678% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -72.301% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1110.639% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -11485.902% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1181.277% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6432.489% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13333.163% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3892.107% |
| Altimmune, Inc. | 210.64 Million USD | -124.035% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 39.334% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -339.441% |
| Compugen Ltd. | 121.33 Million USD | -288.932% |
| Peak Bio, Inc. | 2.59 Million USD | -18075.33% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -173.844% |
| Benitec Biopharma Inc. | 52.21 Million USD | -803.863% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -38.041% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1257.108% |
| Zura Bio Limited | 100.84 Million USD | -367.962% |
| PolyPid Ltd. | 15.37 Million USD | -2969.913% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -295.61% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1257.108% |
| Instil Bio, Inc. | 325.63 Million USD | -44.921% |
| argenx SE | 4.54 Billion USD | 89.611% |
| Immunome, Inc. | 148.54 Million USD | -217.697% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -200.817% |
| Verona Pharma plc | 308.12 Million USD | -53.155% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -442.678% |
| Shattuck Labs, Inc. | 159.56 Million USD | -195.748% |
| CervoMed Inc. | 9.97 Million USD | -4632.073% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -150.407% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -4043.897% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -163.04% |
| Moolec Science SA | 24.05 Million USD | -1862.086% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -7614.075% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -172.866% |
| AnaptysBio, Inc. | 452.38 Million USD | -4.314% |
| Design Therapeutics, Inc. | 289.64 Million USD | -62.927% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -548.001% |
| NeurAxis, Inc. | 509.49 Thousand USD | -92521.953% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -8609.985% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1061.246% |
| Achilles Therapeutics plc | 161.45 Million USD | -192.282% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -442.678% |
| 180 Life Sciences Corp. | 5.25 Million USD | -8872.51% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -570.058% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5412.539% |
| Nutriband Inc. | 7.51 Million USD | -6177.735% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -85.29% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -136.781% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -519.203% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -714.813% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 10.376% |
| Palisade Bio, Inc. | 14.05 Million USD | -3258.291% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -124.402% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 67.671% |
| Neurogene Inc. | 222.57 Million USD | -112.023% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 27.02% |
| AEON Biopharma, Inc. | 6.84 Million USD | -6794.186% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -4.165% |
| Sesen Bio, Inc. | 189.17 Million USD | -149.457% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -73.58% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3341.595% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 39.526% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -76.748% |
| Athira Pharma, Inc. | 160.24 Million USD | -194.491% |
| Vaccinex, Inc. | 3.63 Million USD | -12896.613% |
| HCW Biologics Inc. | 28.51 Million USD | -1555.021% |
| XOMA Corporation | 234.3 Million USD | -101.411% |
| Nektar Therapeutics | 398.03 Million USD | -18.56% |
| Arvinas, Inc. | 1.3 Billion USD | 63.827% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2669.841% |
| Merus N.V. | 458.49 Million USD | -2.925% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -130.913% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -161.874% |
| Rezolute, Inc. | 132.73 Million USD | -255.52% |
| Clene Inc. | 52.34 Million USD | -801.601% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -3062.094% |
| BeyondSpring Inc. | 24.8 Million USD | -1802.237% |
| Synlogic, Inc. | 75.55 Million USD | -524.629% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3878.309% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4939.588% |
| Peak Bio, Inc. | 2.59 Million USD | -18075.33% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -169.919% |
| Krystal Biotech, Inc. | 818.35 Million USD | 42.335% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -96.27% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 34.98% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -13092.173% |
| MannKind Corporation | 475.19 Million USD | 0.693% |
| Ikena Oncology, Inc. | 192.09 Million USD | -145.667% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3428.54% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -304.935% |
| Gossamer Bio, Inc. | 311.91 Million USD | -51.293% |
| CohBar, Inc. | 16.36 Million USD | -2783.518% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1242.056% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6351.224% |
| Legend Biotech Corporation | 1.84 Billion USD | 74.472% |
| Mural Oncology plc | 301.74 Million USD | -56.393% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1411.796% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -8207.629% |
| Disc Medicine, Inc. | 367.99 Million USD | -28.237% |
| Champions Oncology, Inc. | 26.13 Million USD | -1705.859% |
| REGENXBIO Inc. | 573.97 Million USD | 17.782% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -17325.856% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -205.667% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3807.945% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -38.782% |
| Vaxart, Inc. | 91.83 Million USD | -413.892% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -687.774% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -218.153% |
| Cellectis S.A. | 334.27 Million USD | -41.175% |
| Longeveron Inc. | 12.17 Million USD | -3775.078% |
| Repare Therapeutics Inc. | 253.9 Million USD | -85.863% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 85.545% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -134.958% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 77.405% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -28940.431% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -69.927% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -189.34% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -240.128% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1749.02% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.924% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 59.104% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3764.097% |
| Veru Inc. | 50.59 Million USD | -832.698% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -935.952% |
| Cingulate Inc. | 3.49 Million USD | -13416.129% |
| Passage Bio, Inc. | 150.54 Million USD | -213.466% |
| Context Therapeutics Inc. | 16.06 Million USD | -2837.899% |
| Exicure, Inc. | 11.58 Million USD | -3975.19% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -25.491% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -191.946% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2600.933% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -41.822% |
| Nuvalent, Inc. | 732.38 Million USD | 35.566% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -3057.819% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -426.952% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3225.396% |
| OmniAb, Inc. | 401.98 Million USD | -17.394% |
| Anew Medical, Inc. | 19.45 Million USD | -2325.515% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1665.686% |
| Lipocine Inc. | 23 Million USD | -1951.674% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -237.542% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -54.438% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -462.187% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -288.273% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -5847.158% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 46.513% |
| Ocugen, Inc. | 64.54 Million USD | -631.106% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -278.917% |
| Q32 Bio Inc. | 306.11 Million USD | -54.158% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -11114.52% |
| Alumis Inc. Common Stock | 89.61 Million USD | -426.611% |
| Equillium, Inc. | 50.53 Million USD | -833.915% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -527.578% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1043.365% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -27645.314% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1705.237% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -632.309% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -12561.462% |
| Dominari Holdings Inc. | 57.55 Million USD | -719.881% |
| Edesa Biotech, Inc. | 8.89 Million USD | -5208.029% |
| vTv Therapeutics Inc. | 11.01 Million USD | -4183.055% |
| Bio-Techne Corporation | 2.81 Billion USD | 83.225% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 49.643% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 41.844% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -69.956% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1031.617% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 29.312% |
| Nkarta, Inc. | 378.88 Million USD | -24.552% |
| BioCardia, Inc. | 2.98 Million USD | -15698.694% |
| Iterum Therapeutics plc | 26.25 Million USD | -1697.125% |